Lotte Biologics Showcase Global Strengths at BIO Japan 2024
Expanding Partnerships in Antibody Therapeutics and ADCs in the Asia-Pacific Market
Korean CDMO Companies Show Strength at BIO Japan
Each October, Yokohama, Japan, hosts Asia’s largest biotechnology exhibition, "BIO Japan." This global event fosters collaboration in Japan’s bio-healthcare sector, strategically located near the nation’s largest biocluster, the Shonan Health Innovation Park.
Hit News met with representatives from leading Korean biopharmaceutical contract development and manufacturing organizations (CDMOs) at the event to discuss their companies’ competitive strengths and future plans.
① Lotte Biologics Pursues Dual CDMO Strategy with Antibody Therapeutics and ADCs
“Our participation at BIO Japan this year aims to showcase Lotte Biologics’ CDMO expertise to a global audience. We’re actively partnering with potential clients to secure new contracts,” said Sung Jae-in, Global Business Development Manager at Lotte Biologics. Emphasizing the importance of global partnerships, Sung outlined the company’s ambitions to grow in Japan's CDMO market, following its participation in last year’s event.
During BIO Japan, Lotte Biologics pursued partnerships with clients from North America and the Asia-Pacific (APAC) region. “Japan, being the largest APAC market in the pharma-bio sector, is crucial for us. We’re accelerating our efforts here,” Sung noted, adding that meetings with approximately 30 global firms were scheduled with an aim to secure client orders.
Lotte Biologics has committed to investing $3.4 billion by 2030 to establish globally competitive manufacturing capabilities. The company plans to start operating an antibody-drug conjugate (ADC) production facility at its Syracuse Bio Campus in the U.S. by Q1 2025. Sung Jae-in confirmed that the Syracuse campus will complete its validation process by March next year, paving the way for ADC production. “We’re also discussing business opportunities with global ADC companies here at BIO Japan,” he added.
In parallel, Lotte Biologics is constructing an antibody therapeutics bioplant in Songdo, Incheon, targeting a production capacity of 360,000 liters by 2030. The Syracuse campus will function as a one-stop solution for ADC drug manufacturing, while the Songdo Bio Campus will support antibody therapeutics production.
Sung highlighted the strategic advantage of having dual campuses: “Once Songdo is completed, it will offer a ‘dual-site’ advantage with Syracuse, creating a comprehensive offering for our global pharma-biotech partners. We aim to position ourselves strongly with this dual-track strategy focused on antibody therapeutics and ADC CDMO services.”